Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. 

Endo’s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success.

In addition to internal development, our Corporate and Business Development teams routinely evaluate product and company acquisitions, licenses and strategic alliances in order to create a robust portfolio of quality medicines. Please contact us about a potential business development opportunity.

Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,000 people worldwide*. 

*As of 03/30/2018